Autoantibodies to GIPC1 in Breast and Ovarian Cancer
Author Information
Author(s): Yavelsky Victoria, Rohkin Sarit, Shaco-Levy Ruthy, Tzikinovsky Alina, Amir Tamar, Kohn Hila, Delgado Berta, Rabinovich Alex, Piura Benjamin, Chan Gerald, Kalantarov Gavreel, Trakht Ilya, Lobel Leslie
Primary Institution: Ben Gurion University of the Negev
Hypothesis
Can human autoantibodies targeting GIPC1 serve as diagnostic markers for breast and ovarian cancer?
Conclusion
The study shows that GIPC1 protein is overexpressed in ovarian and breast cancer, suggesting its potential as a diagnostic and prognostic marker.
Supporting Evidence
- Antibodies 27.F7 and 27.B1 showed strong binding to malignant breast cancer tissue.
- GIPC1 expression was higher in invasive breast tumors compared to benign tumors.
- The study identified differential staining patterns in borderline ovarian tumors.
Takeaway
Scientists found that a protein called GIPC1 is more common in breast and ovarian cancer, which could help doctors find these cancers earlier.
Methodology
The study used cELISA, flow cytometry, Western blot analysis, immunocytochemistry, and immunohistochemistry to analyze the expression of GIPC1.
Statistical Information
P-Value
<0.001
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website